ut-logo website  
 
Log in
Express registration and login!
If you have a Facebook or LinkedIN account, use one of the buttons on the left to either login or create a new account.

Log in

 

AUA 2012 - Overactive Bladder

AUA 2012 - Neurostimulation treatment for overactive bladder: An evaluation of cost effectiveness data - Slide Presentation

ATLANTA, GA USA (UroToday) - Presented by Presented by Scott MacDiarmid, MD,1 Melissa Martinson, PhD,2 and Edward Black, MBA3 at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA at the American Urological Association (AUA) Annual Meeting- May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

Read more...

AUA 2012 - Neurostimulation treatment for overactive bladder: An evaluation of cost effectiveness data - Abstract

ATLANTA, GA USA (UroToday) - INTRODUCTION AND OBJECTIVES: Neuromodulation for overactive bladder (OAB), including both electrical stimulation of nerves that control bladder function via direct implantable sacral nerve stimulation (SNS), or indirectly via percutaneous tibial nerve stimulation (PTNS), are increasingly recommended in the OAB treatment algorithm.

Read more...

AUA 2012 - Neurostimulation treatment for overactive bladder: An evaluation of cost effectiveness data - Poster

ATLANTA, GA USA (UroToday) - Presented by Scott MacDiarmid, MD,1 Melissa Martinson, PhD,2 and Edward Black, MBA3 at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

macdiarmid neurostimulation poster

Click the image above to view or download the full-size poster

 

1Alliance Urology Specialists, Greensboro, NC
2Technomics Research LLC, Minneapolis, MN
3Reimbursement Strategies LLC, St. Paul, MN

 

 

View full AUA Coverage

 


AUA 2012 - 30 month study results using percutaneous tibial nerve stimulation: Long term efficacy outcomes - Slide Presentation

 

ATLANTA, GA USA (UroToday) - Presented by Kenneth M. Peters, MD,1 Donna J. Carrico, NP, MS,1 Scott MacDiarmid, MD,2 Leslie Saltzstein Wooldridge, NP,3 and Ansar U. Khan MD4 at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

Read more...

AUA 2012 - 30 month study results using percutaneous tibial nerve stimulation: Long term efficacy outcomes - Abstract

ATLANTA, GA USA (UroToday) - INTRODUCTION AND OBJECTIVES: Neuromodulation has become increasingly recommended in the treatment algorithm for patients with OAB and is suited following failure of pharmacotherapy options.

Read more...

AUA 2012 - 30 month study results using percutaneous tibial nerve stimulation: Long term efficacy outcomes - Poster

ATLANTA, GA USA (UroToday) - Presented by Kenneth M. Peters, MD,1 Donna J. Carrico, NP, MS,1 Scott MacDiarmid, MD,2 Leslie Saltzstein Wooldridge, NP,3 and Ansar U. Khan, MD4 at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

Read more...

AUA 2012 - Evaluating patients' symptoms of overactive bladder by questionnaire: The role of urgency on urinary frequency - Session Highlights

ATLANTA, GA USA (UroToday) - As was outlined in this poster, overactive bladder (OAB) is distinguished by urinary urgency, yet many patients cite urinary frequency as their most bothersome symptom. In a OAB pilot study (Abstract #1966) involving 102 patients (87 females and 15 males) with a mean age of 67.4 years, an OAB-q symptom bother scale and patient questionnaire were assessed to determine the most bothersome symptoms. ICS definitions for frequency, urgency, incontinence, and nocturia were applied to relatable statements. When patients indicated “void/urinate too often by day” (the ICS definition for frequency), they were asked why they voided frequently. One of the responses was “a sudden compelling desire to pass urine that is difficult to defer” (the ICS definition for urgency). Other responses included: fear of leakage of urine, sensation of something in the bladder, and learned behavior.

Of those enrolled in the study, 45% are currently taking an anticholinergic (ACH); 43% had not taken an anticholinergic for more than four weeks. Of the assessment tools, the OAB-q bother scale gauged degree of bother at 52.5 (on a scale of 10-100). Nocturia was identified as the most bothersome symptom (27.5%); however, frequency and incontinence (24.5%), followed by urgency (23.5%) were significant complaints. For those not on an ACH, frequency and nocturia were most often the most bothersome complaints. In contrast, for those on an ACH, urgency was the most common symptom. Of those that selected frequency as the most bothersome issue, 52% selected urgency is the underlying reason for the frequency. The study group concluded that urgency is the primary overall complaint with 75% citing urgency as either the primary issue or as a driving symptom behind frequency.

Presented by Benjamin Brucker, Daniella Kaefer, Margarita Aponte, Nirit Rosenblum, Christopher Kelly, Duane Hickling, and Victor Nitti at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA

View full AUA Coverage

 


AUA 2012 - The urodynamic safety of mirabegron based on a phase II bladder outlet obstruction (BOO) clinical trial - Special Report

ATLANTA, GA USA (UroToday) - In his podium presentation, Victor Nitti, MD, NYU Langone Medical Center, reported on the urodynamic safety of mirabegron based on a phase II bladder outlet obstruction (BOO) clinical trial (Abstract 1869).

Read more...

AUA 2012 - AUA guidelines emphasizes behavioral therapies, medications to treat overactive bladder - Press Release

LINTHICUM, MD USA (PRESS RELEASE) - May 23, 2012 - New guidelines released today by the American Urological Association (AUA) emphasize behavioral therapies (such as bladder training, pelvic floor muscle training and fluid management) as a first-line treatment for overactive bladder, followed by medications and neuromodulation.

Read more...